Codexis
Codexis' revenue rose 18.6% to $70 million in fiscal 2025. Its operating margin was −59.3%, up from −98.6% a year earlier. Free cash flow was −$24 million. The diluted share count rose 18.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Codexis does
Codexis engineers enzymes, the natural molecules that drive chemical reactions, using its CodeEvolver directed evolution technology. It focuses on improving how complex medicines are made, in two areas: its ECO Synthesis platform for making RNA interference (RNAi) drugs, and its small molecule pharma biocatalysis business.
ECO Synthesis is a set of enzymatic tools and processes meant to allow large-scale manufacture of RNAi therapeutics, drugs that silence certain genes. In its small molecule business, it develops enzymes that some of the world's largest pharmaceutical companies use to make their manufacturing more efficient.
It says it is testing the feasibility of its process with several partners and expects to advance at least one of them in 2026.
Its biggest risks, as it describes them
- A history of net losses, with no assurance it will become or stay profitable.
- Reliance on a limited number of customers.
- Supply agreements with customers that may not be renewed and need not commit them to buy.
- Regulators may disagree that its products are exempt from drug manufacturing rules.
- Problems or higher costs at its facilities, or in providing complex services.
Income statement
Codexis lost money in fiscal 2025: a net loss of $44 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 117 | 114 | 65 | 74 | 78 |
| Debt incl. finance leases | — | — | 0 | 29 | 40 |
| Net debt (negative means net cash) | — | — | −65 | −45 | −38 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | 0.4x | 0.8x |
| Interest coverage | −1,621.2x | −1,025.9x | −1,547.0x | −22.8x | −13.2x |
| Current ratio | 4.8x | 3.3x | 2.6x | 4.2x | 3.8x |
| Quick ratio | 4.8x | 3.3x | 2.5x | 4.1x | 3.8x |
Cash flow
Projections
Project Codexis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Codexis says to expect
- Full year 2026: total revenues
Total revenues are expected to be in the range of $72 million to $76 million.
- Full year 2026: gross margin
Gross margin for the year 2026 is expected to be in the low 70% range.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Codexis shares on the open market, and 5 insiders sold $933,396.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Alison MoorePresident and CEO, Director | Sold | 10,651 | $1.14 | $12,111 | Form 4 |
| Jun 11, 2026 | Vre Raymond DeDirector | Sold | 2,605 | $2.37 | $6,174 | Form 4 |
| Feb 24, 2026 | Stefan LutzChief Scientific Officer | Sold | 5,862 | $1.13 | $6,624 | Form 4 |
| Feb 6, 2026 | Alison MoorePresident and CEO, Director | Sold | 3,826 | $1.31 | $5,012 | Form 4 |
| Feb 6, 2026 | Stefan LutzChief Scientific Officer | Sold | 2,492 | $1.31 | $3,265 | Form 4 |
| Jan 7, 2026 | Stefan LutzCSO | Sold | 4,685 | $1.70 | $7,964 | Form 4 |
| Dec 1, 2025 | Opaleye Management Inc.10% owner | Sold | 253,533 | $1.67 | $423,400 | Form 4 |
| Nov 28, 2025 | Opaleye Management Inc.10% owner | Sold | 107,490 | $1.75 | $188,108 | Form 4 |
| Nov 26, 2025 | Opaleye Management Inc.10% owner | Sold | 153,318 | $1.74 | $266,773 | Form 4 |
| Nov 21, 2025 | Dennis P WolfDirector | Sold | 8,952 | $1.56 | $13,965 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 9 | 4 of 9 |
| Rule of 40 | −130.7% | −105.9% | −15.3% |
| Altman Z'' | −10.64 | −10.79 | −11.56 |
| Accruals ratio | −12.2% | −11.1% | −16.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | 3 of 9 | 4 of 9 |
Compare
Put Codexis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Codexis | FY25 | 18.6% | −59.3% | −33.9% | −189.5% | — | 4 | |
| Personalis | FY25 | −17.7% | −126.4% | −114.1% | — | — | — | Compare |
| Standard Biotools | FY25 | −6.2% | −129.2% | −96.8% | −41.9% | — | 4 | Compare |
| Harvard Bioscience | FY25 | −8.1% | −56.1% | 6.3% | −56.0% | — | 3 | Compare |
| Alpha Teknova | FY25 | 7.3% | −41.9% | −24.2% | −22.0% | — | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 49 | 50 | 61 | 68 | 69 | 105 | 139 | 70 | 59 | 70 |
| Revenue growth | 16.8% | 2.4% | 21.1% | 13.0% | 0.9% | 51.7% | 32.3% | −49.4% | −15.4% | 18.6% |
| Gross profit | 39 | 36 | 48 | 53 | 55 | 82 | 101 | 57 | 43 | 61 |
| Research and development | 22 | 30 | 30 | 34 | 44 | 56 | 80 | 59 | 46 | 52 |
| Operating income | −9 | −23 | −11 | −12 | −24 | −23 | −35 | −68 | −58 | −42 |
| Net income | −9 | −23 | −11 | −12 | −24 | −21 | −34 | −76 | −65 | −44 |
| Diluted EPS (US$) | −0.21 | −0.50 | −0.21 | −0.21 | −0.40 | −0.33 | −0.51 | −1.12 | −0.89 | −0.50 |
| Diluted shares (millions) | 41 | 46 | 52 | 56 | 59 | 65 | 65 | 68 | 73 | 87 |
| Cash flow | ||||||||||
| Cash from operations | −2 | −9 | −14 | −13 | −16 | −14 | 11 | −53 | −49 | −19 |
| Capital expenditure | 1 | 1 | 3 | 4 | 4 | 14 | 8 | 4 | 4 | 4 |
| Free cash flow | −3 | −10 | −17 | −16 | −20 | −28 | 3 | −57 | −54 | −24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 7 | 8 | 7 | 8 | 12 | 14 | 10 | 13 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 12 | 31 | 32 | 90 | 149 | 117 | 114 | 65 | 74 | 78 |
| Debt incl. finance leases | 0 | 0 | — | — | — | — | — | 0 | 29 | 40 |
| Total assets | 36 | 54 | 79 | 149 | 222 | 246 | 250 | 137 | 149 | 148 |
| Total liabilities | 16 | 29 | 23 | 44 | 52 | 82 | 106 | 50 | 82 | 97 |
| Shareholders' equity | 19 | 24 | 56 | 106 | 170 | 164 | 145 | 87 | 67 | 50 |
| Margins and ratios | ||||||||||
| Gross margin | 80.0% | 71.4% | 79.2% | 77.2% | 80.1% | 78.8% | 72.6% | 81.7% | 72.5% | 86.7% |
| Operating margin | −17.5% | −45.9% | −18.6% | −18.3% | −34.6% | −21.7% | −25.2% | −97.0% | −98.6% | −59.3% |
| Net margin | −17.5% | −46.0% | −17.9% | −17.4% | −34.8% | −20.3% | −24.2% | −108.7% | −110.0% | −62.5% |
| Free cash flow margin | −5.6% | −19.5% | −27.8% | −23.8% | −29.3% | −26.8% | 2.1% | −81.3% | −90.5% | −33.9% |
| Rule of 40 (growth + FCF margin) | 11.2% | −17.0% | −6.7% | −10.8% | −28.4% | 24.9% | 34.5% | −130.7% | −105.9% | −15.3% |
| Return on capital | — | — | — | — | — | — | — | — | −210.7% | −189.5% |
| Return on equity | −40.8% | −105.4% | −26.9% | −14.8% | −17.4% | −12.7% | −21.7% | −65.9% | −85.0% | −74.9% |
| Return on assets | −21.3% | −51.5% | −16.4% | −10.4% | −12.9% | −9.1% | −13.5% | −39.4% | −45.7% | −29.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |